At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed May 14, 2026 at 08:00 ET
Chemomab reported Q1 2026 net loss of $1.8M ($0.003/share) vs $3.3M in Q1 2025, with cash burn reduced to $2.4M. The company highlighted new biomarker data from its Phase 2 SPRING trial suggesting nebokitug may benefit PSC patients with coexisting IBD, and continues pursuing partnership discussions. Cash runway extends through Q1 2027, but at a $13M market cap the stock remains a binary-option on partnership or Phase 3 outcomes.
- Q1 2026 net loss of $1.8M vs $3.3M in Q1 2025; R&D expenses fell to $0.9M from $2.5M as Phase 2 SPRING trial wound down
- Cash, equivalents and short-term deposits of $8.0M as of March 31, 2026, down from $10.4M at year-end 2025; runway through Q1 2027
- New biomarker data from SPRING trial presented at DDW 2026 and upcoming EASL 2026 suggest nebokitug modulates gut-liver inflammatory pathways relevant to PSC-IBD comorbidity
- Company continues advancing multiple partnering options for nebokitug; no definitive partnership announced
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access